Blurbs

Analysts Offer Insights on Healthcare Companies: Aileron Therapeutics (ALRN) and OrthoPediatrics (KIDS)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Aileron Therapeutics (ALRNResearch Report) and OrthoPediatrics (KIDSResearch Report).

Aileron Therapeutics (ALRN)

H.C. Wainwright analyst Edward White maintained a Hold rating on Aileron Therapeutics today. The company’s shares closed last Tuesday at $0.20, close to its 52-week low of $0.13.

According to TipRanks.com, White has 0 stars on 0-5 stars ranking scale with an average return of -24.8% and a 23.7% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Aeglea Biotherapeutics.

The the analyst consensus on Aileron Therapeutics is currently a Hold rating.

See today’s best-performing stocks on TipRanks >>

OrthoPediatrics (KIDS)

In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on OrthoPediatrics, with a price target of $62.00. The company’s shares closed last Tuesday at $37.36, close to its 52-week low of $36.71.

According to TipRanks.com, Zimmerman is a 4-star analyst with an average return of 4.9% and a 41.3% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Treace Medical Concepts, Zimmer Biomet Holdings, and Organogenesis Holdings.

Currently, the analyst consensus on OrthoPediatrics is a Strong Buy with an average price target of $61.20, a 52.6% upside from current levels. In a report issued on October 17, Truist Financial also maintained a Buy rating on the stock with a $52.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ALRN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More